Stockscreener 앱 받기
1.90
2.56%
-0.05
시간 외 거래:
1.93
0.03
+1.58%
전일 마감가:
$1.95
열려 있는:
$1.93
하루 거래량:
693.27K
Relative Volume:
0.57
시가총액:
$73.08M
수익:
$55,200
순이익/손실:
$-19.39M
주가수익비율:
-2.972
EPS:
-0.6393
순현금흐름:
$-17.30M
1주 성능:
-30.91%
1개월 성능:
+0.53%
6개월 성능:
+20.25%
1년 성능:
-23.08%
1일 변동 폭
$1.855
$1.98
1주일 범위
$1.8501
$2.87
52주 변동 폭
$1.41
$4.34
게인 테라퓨틱스 Stock (GANX) Company Profile
명칭
Gain Therapeutics Inc
전화
(301) 500-1556
주소
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.90 | 75.00M | 55,200 | -19.39M | -17.30M | -0.6393 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
게인 테라퓨틱스 Stock (GANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-08-14 | 재개 | Oppenheimer | Outperform |
| 2021-04-12 | 개시 | BTIG Research | Buy |
| 2021-04-12 | 개시 | Oppenheimer | Outperform |
게인 테라퓨틱스 주식(GANX)의 최신 뉴스
Gain Therapeutics to Present at the 38th Annual ROTH Conference - The Manila Times
Gain Therapeutics, Inc. CEO Gene Mack to Speak at 38th Annual ROTH Conference - Quiver Quantitative
Gain CEO Gene Mack to speak at ROTH conference on March 23 - Stock Titan
Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday - MarketBeat
Gain Therapeutics reports biomarker data from Parkinson’s trial By Investing.com - Investing.com South Africa
Gain announces presentations on Phase 1b clinical study of GT-02287 - TipRanks
Gain Therapeutics, Inc. (GANX): Emerging Biomarker Data Strengthens Parkinson’s Drug Pipeline - parameter.io
Gain Therapeutics Presents Positive Phase 1b Results for GT-02287 in Parkinson’s Disease and Advances New GCase Modulators for Clinical Development 123 - Minichart
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data - TipRanks
Gain Presents Phase 1b GT-02287 Data Showing biomarker changes, MDS-UPDRS stability; GT-04686 ready for IND - TradingView
Gain Therapeutics (NASDAQ: GANX) unveils new Parkinson’s trial and biomarker data - Stock Titan
Gain Therapeutics reports biomarker data from Parkinson’s trial - Investing.com
Parkinson’s trial drug sees symptoms hold steady over 5 months - Stock Titan
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Can Gain Therapeutics Inc stock double in the next yearWeekly Investment Summary & Expert Curated Trade Ideas - baoquankhu1.vn
Aug Drivers: Whats the beta of Gain Therapeutics Inc stock2026 Weekly Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7%What's Next? - MarketBeat
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% – What’s Next? - Defense World
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Analysts’ Top Healthcare Picks: Gain Therapeutics (GANX), Relmada Therapeutics (RLMD) - The Globe and Mail
Gain Therapeutics (GANX) upgraded to buy: Here's why - MSN
Is Gain Therapeutics Inc vulnerable to short sellersWeekly Profit Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update - Bitget
Market Recap: Is Gain Therapeutics Inc part of any major indexWeekly Gains Report & Risk Managed Investment Signals - baoquankhu1.vn
GANX Technical Analysis & ETF Price Forecast - Intellectia AI
What makes Gain Therapeutics Inc. stock attractive to growth fundsCEO Change & Expert Curated Trade Ideas - Naître et grandir
Pharma News: Can Gain Therapeutics Inc continue delivering strong returnsMarket Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Bearish Setup: What is Gain Therapeutics Incs 5 year growth outlookTrade Analysis Report & AI Powered Market Entry Ideas - baoquankhu1.vn
Gyre Therapeutics Enters into Agreement to Acquire Cullgen - GlobeNewswire
GANX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Voyager Therapeutics Inc. stock gain from lower inflationTrade Analysis Report & Daily Oversold Stock Bounce Ideas - mfd.ru
Celldex Therapeutics Opens with a 6.56% Gain, Outpacing S&P 500's 0.69% Increase - Markets Mojo
Stoke Therapeutics Opens with 6.45% Gain, Outperforming S&P 500's 0.69% - Markets Mojo
GANX PE Ratio & Valuation, Is GANX Overvalued - Intellectia AI
Intellia Therapeutics Opens with 6.49% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo
Beam Therapeutics Opens with 7.83% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo
Gain Therapeutics to Present Key Clinical Program Updates at Oppenheimer Conference - AD HOC NEWS
Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views - Benzinga
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - 富途牛牛
What’s the beta of Gain Therapeutics Inc. stock2025 Short Interest & Detailed Earnings Play Alerts - mfd.ru
What’s the analyst consensus on Gain Therapeutics Inc.Weekly Trade Review & Risk Controlled Swing Alerts - mfd.ru
Can Gain Therapeutics Inc. stock double in the next yearBreakout Watch & Weekly High Return Forecasts - mfd.ru
Aug Summary: Is Gain Therapeutics Inc stock a falling knife or bargain buyJuly 2025 Technicals & Growth-Oriented Investment Plans - baoquankhu1.vn
What dividend safety score for Gain Therapeutics Inc. stockWeekly Profit Analysis & High Accuracy Trade Alerts - mfd.ru
Market Fear: Is Gain Therapeutics Inc a strong candidate for buy and holdAnalyst Upgrade & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 19.9% in January - MarketBeat
Published on: 2026-02-16 00:03:51 - mfd.ru
Is Gain Therapeutics Inc. benefiting from innovation trendsJuly 2025 Sentiment & Fast Entry High Yield Stock Tips - mfd.ru
Will Edgewise Therapeutics Inc. stock gain from government policies2025 Fundamental Recap & Reliable Entry Point Trade Alerts - mfd.ru
Insider Trends: Whats the beta of Themes Etf Trust Leverage Shares 2x Long Panw Daily Etf stockPortfolio Gains Report & Safe Entry Trade Signal Reports - baoquankhu1.vn
게인 테라퓨틱스 (GANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):